Full Breakdown
Cannabis Compounds Show Promise in Treating Chronic Liver Disease
3/10/2026, 4:31:28 AM
Research Findings on Cannabinoids and Liver Health
A study conducted by researchers at the Hebrew University of Jerusalem has revealed that compounds found in cannabis, specifically cannabidiol (CBD) and cannabigerol (CBG), may offer new treatment options for metabolic dysfunction-associated steatotic liver disease (MASLD), a chronic liver disorder affecting approximately one-third of adults globally. The findings, published in the *British Journal of Pharmacology*, indicate that both CBD and CBG significantly reduced liver fat and improved metabolic health in experimental models. Unlike tetrahydrocannabinol (THC), the primary psychoactive component of cannabis, CBD and CBG do not produce a "high," making them potential candidates for long-term medical use.
The study highlights a process termed "metabolic remodeling," where these cannabinoids enhance liver function by increasing levels of phosphocreatine, a high-energy molecule. This energy reserve allows the liver to better cope with the stress of a high-fat diet. Additionally, CBD and CBG were found to restore the activity of cathepsins, enzymes that help break down harmful fats and waste within liver cells, thereby improving the organ's ability to clear out dangerous lipids associated with inflammation.
Implications for Treatment
The research suggests that CBD and CBG could pave the way for plant-based therapies targeting metabolic diseases, particularly for patients who currently rely on lifestyle changes that are often difficult to maintain. CBG, in particular, demonstrated more pronounced effects in reducing total body fat mass, lowering "bad" LDL cholesterol, and enhancing insulin sensitivity.
Limitations and Cautions
Despite these promising results, the research team emphasized the need for further clinical trials to evaluate the efficacy of these compounds in human patients. A comprehensive analysis published in *JAMA* reviewed over 2,500 studies on medical marijuana and highlighted significant gaps between public perception and scientific evidence regarding its effectiveness for various medical conditions. The review concluded that only a few conditions have well-established benefits from cannabinoid therapies, primarily those approved by the FDA for specific uses such as HIV/AIDS-related appetite loss and chemotherapy-induced nausea.
Criticism and Expert Opinions
Experts caution against viewing cannabis as a universal remedy. Dr. Alex Dimitriu, a double board-certified psychiatrist and sleep medicine specialist, noted, "This study points to the reality that this widely used substance is not a panacea." He emphasized the importance of consulting healthcare providers before considering cannabis for medical purposes, as potential risks and benefits must be carefully weighed.
What's Next
As research continues, the focus will shift to conducting clinical trials that assess the applicability of CBD and CBG in treating MASLD and other metabolic disorders. The outcomes of these studies could significantly influence future therapeutic strategies in managing chronic liver diseases.
Verbatim Quotes
- “Our findings identify a new mechanism by which CBD and CBG enhance hepatic energy and lysosomal function,” — Joseph Tam, Director, Multidisciplinary Center for Cannabinoid Research, Hebrew University.
- “Whenever a substance is widely used, there is likely to be a very wide set of outcomes,” — Dr. Alex Dimitriu, Founder, Menlo Park Psychiatry & Sleep Medicine.
